Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

Eva Segelov, Prunella Blinman, Andrew J. Martin, David P. Goldstein, Michelle Cronk, David Boadle, Niall Tebbutt, James Paul, Andrew Haydon

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
Publication statusPublished - 2018
EventAmerican Society for Clinical Oncology 2018: ASCO 2018 - McCormick Place, Chicago, United States of America
Duration: 1 Jun 20185 Jun 2018

Conference

ConferenceAmerican Society for Clinical Oncology 2018
Country/TerritoryUnited States of America
CityChicago
Period1/06/185/06/18

Cite this